Core Viewpoint - The Schwab US Dividend Equity ETF (SCHD) has a significant asset base of over $83 billion but is limited by its low dividend yield of 3.5%, prompting investors to consider alternative ETFs with higher yields [1][2][3]. Group 1: SCHD ETF Overview - SCHD ETF has accumulated over $83 billion in assets, making it one of the largest dividend funds in the U.S. [1] - The fund tracks the Dow Jones US Dividend 100 Index, focusing on companies with strong dividend growth [2]. - Despite outperforming the S&P 500 this year, its yield of 3.5% is lower than other funds and short-term government bonds [3]. Group 2: Alternative ETFs - NEOS S&P 500 High Income ETF (SPYI) offers a high dividend yield of 12.8% and has over $7.92 billion in assets [4]. - SPYI employs a covered call strategy, investing in S&P 500 companies and generating returns through call options, but has a higher expense ratio of 0.68% [5][6]. - JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) has a dividend yield of 11.40% and over $33 billion in assets, also using a covered call strategy with a lower expense ratio of 0.35% [7]. - Cohen & Steers Infrastructure Fund (UTF) provides a 10% dividend yield with over $3.7 billion in assets, utilizing leverage as a closed-end fund, but has a high expense ratio of 3.43% [9][10].

Core Viewpoint - The ongoing conflict in Iran has led to a significant decline in traditional safe-haven assets, prompting investors to seek alternative strategies to protect their portfolios amid rising volatility and political uncertainty [2][3][9]. Summary by Category Traditional Safe Havens - Gold and silver, typically seen as safe-haven assets, have experienced substantial declines, with SPDR Gold Shares (GLD) down over 14% and iShares Silver Trust (SLV) down more than 25% since the conflict began [3]. - Bonds, which are usually considered a safe harbor, have also faltered, with Vanguard Total Bond Market ETF (BND) down 2.2% this year, and the yield on the 10-year Treasury rising to 4.34% from 3.96% prior to the war [8]. Dividend-Paying Stocks - Dividend-paying stocks, often viewed as a buffer against political turmoil, have seen a decline, with Schwab U.S. Dividend Equity ETF (SCHD) down more than 4% since the onset of hostilities [5]. - The utilities sector, known for stable cash flows, has not fared much better, with State Street Utilities Select Sector SPDR (XLU) down nearly 4% [6]. Sector Performance - Among the 11 S&P 500 sectors, only the energy sector has shown positive performance, with State Street Energy Select Sector SPDR (XLE) up nearly 11% and United States Oil Fund (USO) experiencing a 58% increase due to rising oil prices [7][10]. - The overall performance of the S&P 500 has been negative, with the State Street SPDR S&P 500 ETF Trust (SPY) down 7.9% since the beginning of the conflict [10]. Cryptocurrency - Cryptocurrency, particularly Bitcoin, has shown resilience, with iShares Bitcoin Trust (IBIT) gaining 1.3% since the start of the war, positioning it as a potential alternative to traditional safe havens [4].

Group 1 - The article discusses the experience of Rida Morwa, a former investment and commercial banker with over 35 years of experience, who has been advising clients on high-yield investment strategies since 1991 [1] - Rida Morwa leads the Investing Group High Dividend Opportunities, focusing on sustainable income through high-yield investments with a targeted safe yield of over 9% [1] - The service includes features such as a model portfolio with buy/sell alerts, preferred and baby bond portfolios for conservative investors, and regular market updates [1] Group 2 - The article mentions that the recommendations provided are closely monitored, and buy/sell alerts are issued exclusively to members [3] - It emphasizes the importance of community and education in investment, suggesting that investors should not invest alone [1]

SideChannel Deploys AI Across Sales, Marketing, and Cybersecurity Delivery Operations <!-- Twitter Tags --> <!-- Facebook Tags --> <!-- Injecting site-wide to the head --> <!-- End Injecting site-wide to the head --><!-- Inject secured cdn script --> <!-- ========= Meta Tags ========= --> <!-- PWA settings --> <!-- Add manifest --> <!-- End PWA settings --> <!--Add favorites icons--><!-- End favorite icons --> <!-- render the required CSS and JS in the head section --> <!-- loadCSS function header.jsp--> <! ...

Group 1: Company Performance - Palantir Technologies experienced a 70% year-over-year revenue growth, reaching $1.4 billion in the fourth quarter of 2025 [1] - Despite the revenue growth, Palantir's share price has declined by 29% since its peak of $207 on November 3, 2025, primarily due to its high valuation [1] - The company has a market capitalization of $353 billion and trades at 233 times trailing earnings, significantly higher than competitors like Microsoft and IBM, which trade at 23 and 22 times trailing earnings, respectively [2] Group 2: Technology and Innovation - Palantir employs a unique approach to data analytics using ontologies, which are visual representations of data that enhance decision-making [3] - The company offers an Artificial Intelligence Platform (AIP) that enables organizations to deploy large language models and AI agents within their private networks [3] Group 3: Government Contracts - Palantir has secured a significant contract with the U.S. Army worth up to $10 billion over the next decade, indicating its growing role in defense [4] - The Pentagon has officially recognized Palantir's Maven system as a program of record, facilitating its adoption across the U.S. military [4] Group 4: Investment Considerations - While Palantir has shown impressive growth and has strong defense contracts, its high valuation necessitates near-perfect execution to maintain its share price [5] - Analysts from The Motley Fool Stock Advisor have identified other stocks as better investment opportunities, suggesting caution for potential investors in Palantir [6]

Group 1 - The spice maker and Unilever are in discussions regarding a cash-and-stock deal [1] - The announcement of the deal could occur as early as Tuesday [1]

Core Insights - Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company is conducting a Phase 3 clinical study for avexitide, which targets adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery [1][4] Clinical Trial Details - The Phase 3 Lucidity clinical study of avexitide has randomized and dosed its final subject, with a total of 78 participants enrolled [2] - The study is designed as a 16-week multicenter, randomized, double-blind, placebo-controlled trial, with the possibility of extending for an additional 32 weeks if participants complete the initial phase [2] - Topline data from the trial is expected to be released in the third quarter of 2026, with avexitide anticipated to be available for sale in 2027 if approved [2] Analyst Insights - H.C. Wainwright analyst Andrew Fein has raised the price target for Amylyx Pharmaceuticals from $28 to $34, maintaining a Buy rating on the shares [2] - The firm has increased its probability of success estimate for the avexitide program, indicating heightened confidence in its potential [3] Company Focus - Amylyx Pharmaceuticals specializes in the discovery and development of treatments for endocrine and neurodegenerative diseases, with a portfolio that includes AMX0318 (avexitide), AMX0035, and AMX0114 at various stages of clinical trials [4]

Group 1 - Collegium Pharmaceutical Inc. has entered into an agreement with Corium Therapeutics Holdings for the acquisition of AZSTARYS, involving $650 million in cash payments and potential earn-out considerations of up to $135 million [1][2] - The acquisition is expected to diversify the company's revenue streams beyond pain medicines and strengthen its position in the ADHD market, contributing to revenue through the late 2030s [2] - Collegium's existing operational and marketing capabilities in ADHD are anticipated to enhance margins and increase operating leverage following the acquisition [2] Group 2 - Collegium Pharmaceutical Inc. has been named an official partner of Boston Legacy FC, establishing a multi-year partnership aimed at improving fan experience during home games [3] - The partnership includes the creation of the Collegium Sensory Room at Gillette, Centreville, and White Stadium, designed to provide a peaceful environment for fans during matches [4] - This initiative aims to enhance the overall experience for visitors by offering a safer and more comfortable setting away from the intense match environment [4] Group 3 - Collegium Pharmaceutical Inc. specializes in the development and commercialization of pain management medicines, offering a diverse product range including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic [5]

Group 1 - Bausch Health Companies Inc. (NYSE:BHC) is recognized as one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds [1] - Analyst Glen Santangelo from Barclays reduced the price target on Bausch Health from $8 to $7, maintaining an Equal Weight rating, indicating an adjusted upside potential of almost 37% despite the revision [1][2] - The company's fourth quarter report showed year-on-year growth in key financial metrics, attributed to its commercial and operational strength [3] Group 2 - CEO Thomas Appio highlighted the potential of the newly acquired full-service aesthetics distribution business in China, which enhances the company's geographical reach and customer access [3] - Bausch Health operates in various segments including hepatology, neurology, dermatology, gastroenterology, generic pharmaceuticals, over-the-counter items, aesthetic medical devices, and eye health [3] - The company is committed to commercial and operational excellence and aims to expand its portfolio and enhance its long-term outlook as it moves into 2026 [3]

Core Insights - Pacira BioSciences Inc. (NASDAQ:PCRX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company presented data at the AAOS 2026 Annual Meeting, showcasing Exparel's benefits in pain management, including improved outcomes, reduced opioid use, and shorter hospital stays compared to standard treatments [1] - Iovera demonstrated longer-lasting pain relief and functional improvement, with benefits lasting up to 12 months, reinforcing the company's position in post-surgical pain management [3] Legislative Impact - A survey conducted by the Voices for Non-Opioid Choices coalition revealed the initial effects of the NOPAIN Act, which was implemented on January 1, 2025 [4][5] - 85% of facility representatives surveyed were aware of the NOPAIN Act, and over half of the facilities have made changes to increase the use of non-opioid options [5] - More than 80% of those surveyed reported a reduction in opioid prescribing for immediate post-surgery and discharge due to the legislation [5] Company Focus - Pacira BioSciences is dedicated to developing and marketing non-opioid pain management and regenerative health solutions, with a portfolio that includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device [6]